<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03699215</url>
  </required_header>
  <id_info>
    <org_study_id>LEVOCEST</org_study_id>
    <nct_id>NCT03699215</nct_id>
  </id_info>
  <brief_title>Clinical Trial in Patients Who Have Suffered a Heart Attack and Who Have Undergone Catheterization Treated With Levosimendan</brief_title>
  <acronym>LEVOCEST</acronym>
  <official_title>Ensayo clínico, Fase III, Aleatorizado, Prospectivo, unicéntrico, Doble Ciego y Controlado Con Placebo, Para Estimar la Eficacia y Seguridad Del Levosimendan Intravenoso, en Las Primeras 24 Horas Tras la Angioplastia Primaria, en Pacientes Con síndrome Coronario Agudo Con elevación Del Segmento ST</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The disease under study is acute coronary syndrome with ST segment elevation, defined as&#xD;
      patients presenting chest pain of anginal characteristics of more than 20 minutes of&#xD;
      duration, with changes in the electrocardiogram consisting of ST segment elevation of 1 mm in&#xD;
      two contiguous limb leads or 2 mm in two contiguous leads precordial. In a review carried out&#xD;
      on patients treated in the investigator center with SCACEST, invetsigators found that, in a&#xD;
      cohort of 250 patients, 85% of them presented alterations Segments of left ventricular&#xD;
      contractility at 4 months after the acute episode. To verify that the Levosimendan&#xD;
      administration reduces that percentage, at least 65%, investigators require to include in the&#xD;
      study 83 patients in the experimental group and 83 in the control group, for a power of 80%&#xD;
      and a confidence level of 95%. Assuming 10% of lost patients, it is required to include in&#xD;
      the study 92 patients in the experimental group and 92 patients in the group control .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients will be included randomly, until the calculated sample size is completed. A&#xD;
      recruitment period of 12 months is estimated from the beginning of the study. From the date&#xD;
      of inclusion of the first patient, the final duration of the study will be 1.5 years.&#xD;
&#xD;
      The study will end when performing the last cardio-resonance and echocardiography that should&#xD;
      be performed 6 months after the inclusion of the last patient in the study.&#xD;
&#xD;
      Upon arrival of the patient at the Coronary Unit, he will receive, in a randomized and&#xD;
      double-blind manner, without a loading dose, the 24-hour infusion of Levosimendan, or&#xD;
      placebo.&#xD;
&#xD;
      The continuous infusion of levosimendan 0.1 micrograms / kg / min will be administered during&#xD;
      24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the&#xD;
      infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan&#xD;
      infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic&#xD;
      hypotension &lt;90 mmHg.&#xD;
&#xD;
      Continuous perfusion of the placebo 0.1 micrograms / kg / min will be administered for 24h.&#xD;
      If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion&#xD;
      rate can be increased to 0.2 micrograms / kg / min. The dose of infusion of the placebo can&#xD;
      be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension &lt;90&#xD;
      mmHg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Size of acute myocardial infarction</measure>
    <time_frame>30 days after acute episode</time_frame>
    <description>percentage myocardium infarct/ left ventricle ventricle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measurement of Biochemical parameters function</measure>
    <time_frame>first 24 hours</time_frame>
    <description>troponine, creatinkinase, creatinkinase-MB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>electrocardiogram parameters</measure>
    <time_frame>1 hour after primary angioplasty</time_frame>
    <description>Residual ST segment deviation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAJOR CARDIAC EVENTS</measure>
    <time_frame>6 months after angioplasty</time_frame>
    <description>need of revascularitation or cardiac death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>solution for intravenous infusion, with similar organoleptic characteristics than active treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concentrate for solution for perfusion. Pack with a 5 ml vial</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Upon arrival of the patient in the Coronary Unit, he will receive, in a randomized and double-blind manner, the 24-hour infusion of Levosimendan, without a loading dose, at a dose of 0.1 μg / kg / min or placebo. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min. The dose of Levosimendan infusion can be reduced to 0.05 μg / kg / min in case of clinical intolerance or systolic hypotension &lt;90 mmHg.</description>
    <arm_group_label>levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both sexes who come to CHUC.&#xD;
&#xD;
          -  Age between 18 and 85 years old.&#xD;
&#xD;
          -  Symptoms of STEMI over 30 minutes and less than 12 hours of evolution.&#xD;
&#xD;
          -  ST segment elevation of &gt;= 1 mm in two contiguous limb leads or &gt;= 2 mm in two&#xD;
             contiguous precordial leads.&#xD;
&#xD;
          -  Patients agreed to participate in the study and have signed the informed consent.&#xD;
&#xD;
          -  The same patient may not be included more than once.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Killip IV class in a situation of cardiogenic shock or with TAM values below 65 mmHg&#xD;
             of pressure.&#xD;
&#xD;
          -  Patients that have suffered a previous heart attack.&#xD;
&#xD;
          -  Patients who are being administered amines.&#xD;
&#xD;
          -  Patients that do not have segmental disorders of contractility in left&#xD;
             ventriculography.&#xD;
&#xD;
          -  Mental circumstance that makes you unable to participate in the study.&#xD;
&#xD;
          -  Patients that refuse to participate in the study and that they do not sign the&#xD;
             informed consent.&#xD;
&#xD;
          -  Severe renal impairment (creatinine clearance &lt;30ml / min)&#xD;
&#xD;
          -  Severe hepatic insufficiency - (prothrombin activity rate &lt;40%).&#xD;
&#xD;
          -  History of Torsades de Pointes.&#xD;
&#xD;
          -  Acute respiratory distress&#xD;
&#xD;
          -  Allergy to levosimendan or some of its components&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;8g / dl)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Francisco Bosa Ojeda, MD PhD</last_name>
    <phone>00 34 922678457</phone>
    <phone_ext>34457</phone_ext>
    <email>franbosa@ull.edu.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Consuelo Rodríguez Jiménez, MD PhD</last_name>
    <phone>922678573</phone>
    <email>conrodjim@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UICEC</name>
      <address>
        <city>La Laguna</city>
        <state>S/C De Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Consuelo Rodríguez Jimnénez, PhD, MD</last_name>
      <phone>922678175</phone>
      <email>conrodjim@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

